Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

11 Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Pipeline Insights Forecast & Analysis 2016

 



(PharmaNewsWire.Com, January 05, 2017 ) Publisher's, "11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors. The Publisher's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors. Publisher's Report also assesses the 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

For more information about this report: http://www.reportsweb.com/11-beta-hydroxysteroid-dehydrogenase-inhibitors-pipeline-insights-2016

Report Scope

- The report provides competitive pipeline landscape of 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reason to Buy

- Complete MOA intelligence and complete understanding over therapeutics development for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidencebased Decisions

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001338764/sample

Table of Contents

- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Overview
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Disease Associated
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Pipeline Therapeutics
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Therapeutics under Development by Companies
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Filed and Phase III Products
- Comparative Analysis
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Phase II Products
- Comparative Analysis
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors - Discontinued Products
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors

Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001338764/buying

ReportsWeb.com

Priya Sisodia

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC